Special Issue

Veterinary Antiparasitic Vaccines

Message from the Guest Editors

This Special Issue of Vaccines will address the emerging field of veterinary antiparasitic vaccines, responding to a significant unmet need in animal health. This Special Issue will examine the scientific, technological, economic, and regulatory challenges faced in developing these unprecedented vaccines. It will highlight the scientific rationale behind these vaccines, the complexities of manufacturing these novel biologicals, and broader considerations within a One Health context, considering how parasites affect the interconnected health of humans, animals, and ecosystems. Additionally, this Special Issue will emphasize the necessity of establishing a regulatory pathway tailored to the unique characteristics of antiparasitic vaccines, as current frameworks designed for drugs are inadequate. By bringing together expert perspectives, the main aim is to provide a comprehensive overview of critical issues regarding advances in veterinary antiparasitic vaccines in order to contribute to the health and well-being of animals and, by extension, global public health. I look forward to receiving your contributions.

Guest Editors

Dr. Miriam Tendler

Laboratory of Anti-Helminth Vaccine Research and Development, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21045-900, Brazil

Dr. Marília Sirianni dos Santos Almeida

Laboratory of Anti-Helminth Vaccine Research and Development, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21045-900, Brazil

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/235637

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

